Drug intelligence / Profile preview

AM-01

Development stage: Preclinical
Lead developer: Amani Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**AM-01** is an investigational fixed-dose small-molecule combination being developed by Amani Therapeutics for schizophrenia. It combines clozapine with an undisclosed Phase 3-ready novel chemical entity in-licensed from AstraZeneca under worldwide rights. The program is intended to preserve clozapine's antipsychotic efficacy while mitigating clozapine-associated severe neutropenia and reducing the blood-monitoring burden that limits clozapine use.

Targets

mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on AM-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-01.

Explore the full profile